Point72 Europe London LLP Grows Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Point72 Europe London LLP boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 41,734 shares of the company's stock after purchasing an additional 7,164 shares during the period. Point72 Europe London LLP owned approximately 0.09% of Axsome Therapeutics worth $3,531,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Strategic Financial Concepts LLC acquired a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $2,599,000. Intech Investment Management LLC lifted its position in Axsome Therapeutics by 46.5% during the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock worth $1,356,000 after acquiring an additional 5,087 shares during the period. Raymond James Financial Inc. acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $14,771,000. Charles Schwab Investment Management Inc. grew its stake in shares of Axsome Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after purchasing an additional 5,438 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $395,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 22.30% of the stock is owned by corporate insiders.

Axsome Therapeutics Trading Down 1.9%

Shares of Axsome Therapeutics stock opened at $103.67 on Thursday. Axsome Therapeutics, Inc. has a 1 year low of $64.11 and a 1 year high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The business has a 50 day moving average price of $110.96 and a 200 day moving average price of $104.84. The company has a market capitalization of $5.10 billion, a P/E ratio of -17.31 and a beta of 0.46.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. Sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AXSM. HC Wainwright decreased their price target on Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Morgan Stanley boosted their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Wells Fargo & Company restated an "overweight" rating and issued a $165.00 price target (up from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Cantor Fitzgerald upgraded Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday. Finally, Robert W. Baird upped their price target on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $172.14.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.